Roundup is a popular herbicide widely used by farmers, landscapers, and homeowners to control weeds. Its active ingredient, glyphosate, has been classified as a probable human carcinogen by the World Health Organization’s International Agency for Research on Cancer (IARC). Studies have linked glyphosate exposure to various types of cancer, including non-Hodgkin lymphoma (NHL) and other serious health conditions.
Roundup lawsuits allege that Monsanto, the manufacturer of Roundup, failed to warn users about the potential health risks associated with glyphosate exposure. It is claimed that the company knew about the link between Roundup and cancer but chose to prioritize profits over public safety. These lawsuits further allege that Monsanto manipulated scientific studies and downplayed the risks associated with glyphosate.
By filing a Roundup lawsuit, you can seek compensation for medical expenses, lost wages, pain and suffering, and other damages resulting from your illness. Additionally, these lawsuits aim to hold Monsanto accountable for its actions and send a message that negligent corporations should be held responsible for the harm they cause to consumers and the environment.
For the start of November, there have been no significant new developments in the Monsanto Roundup litigation. The most recent notable events occurred in October 2024, including a Philadelphia jury awarding $78 million to a plaintiff who developed non-Hodgkin’s lymphoma after using Roundup. Additionally, the Fifth Circuit Court upheld a summary judgment in favor of Monsanto in a separate case. No major verdicts, settlements, or regulatory changes have been reported, we will wait to hear more for important updates.
Plaintiffs argue that Monsanto, now owned by Bayer AG, failed to adequately warn users about the potential cancer risks associated with prolonged Roundup exposure, despite scientific findings suggesting such hazards. In response, Bayer has continually challenged these allegations, maintaining that glyphosate is safe when used as directed, a stance largely upheld by certain regulatory bodies.
Throughout 2024, Bayer has faced pressure as various courts grapple with the intricacies of causation, liability, and evidence in Roundup cases. While some jurisdictions have awarded substantial verdicts to plaintiffs, others have encountered procedural challenges that complicate the litigation landscape. The company has sought to manage claims through settlement offers and even proposed a compensation fund, yet many victims believe these measures fall short of addressing the full scope of harm experienced.
For claimants, the pathway to resolution remains a complex and demanding process. The consolidation of cases within multi-district litigation (MDL) has streamlined some aspects, allowing plaintiffs’ counsel to pursue coordinated discovery and expert testimonies on glyphosate’s effects. Still, the ongoing legal battles and mixed rulings underscore the need for precise, individualized representation considering emerging scientific evidence and shifting legal precedents.
Looking forward, the outcomes of upcoming trials may set significant precedents for both existing and future cases. Bayer’s legal team continues to advocate for glyphosate’s safety, likely preparing for appeals and further negotiations. For those affected, keeping watch of these development is essential, as each decision could influence compensation prospects and set the tone for accountability in product liability litigation against large corporations like Bayer.
There are currently 4,337 Roundup lawsuit cases still open in federal multidistrict litigation (MDL) in California. Although Bayer had previously offered a $10.9 billion settlement in 2020 to resolve about 100,000 cases, new cases continue to be filed, and many remain unresolved. In recent months, plaintiffs have secured substantial verdicts against Bayer, including a $2.25 billion award in January 2024 to a Pennsylvania man who claimed Roundup caused his non-Hodgkin lymphoma.
In September 2024, Bayer achieved a win in Missouri when an appeals court upheld the original ruling in a Roundup case, rejecting the plaintiff’s claims that errors in the original trial influenced the outcome. Meanwhile, in August 2024, the 3rd U.S. Circuit Court of Appeals in Philadelphia ruled in favor of Bayer, stating that federal pesticide labeling laws preempt state laws requiring cancer warnings on Roundup labels. This decision creates a split among circuit courts, increasing the likelihood of a potential Supreme Court review.
Recent studies have highlighted potential health risks associated with glyphosate, Roundup’s active ingredient. French researchers published findings suggesting that glyphosate may impact human fertility. Additionally, Bayer has been lobbying Congress to include protective language in an upcoming farm bill that would shield it from further lawsuits related to Roundup’s alleged cancer risks. These efforts have seen mixed results, with some state legislatures rejecting similar protective measures.
Bayer continues to face a mixed legal landscape. While the company has seen several favorable verdicts in state courts recently, such as a defense verdict in a wrongful death trial in Arkansas, other rulings have gone against it. A recent case in Oregon saw an appeals court overturn a prior Bayer victory, citing errors in excluding certain testimonies related to EPA regulations. The ongoing trials indicate that Bayer’s litigation strategy is still evolving, and the outcomes remain uncertain. It’s important to reach out to legal representation if you feel you were affected by Roundup exposure and are still currently dealing with health problems. We ensure that we will fight for your rights and continue to update you on this litigation.
The ongoing litigation surrounding Monsanto’s Roundup weed killer continues to develop, with several important updates emerging in August. These lawsuits, primarily focused on claims that exposure to Roundup causes cancer, particularly non-Hodgkin lymphoma, have seen significant legal activity across various jurisdictions.
In a notable development, a Philadelphia judge recently reduced a staggering $2.25 billion verdict awarded in January 2024 to $400 million. While this reduction is considerable, it still underscores the magnitude of the financial risk that Bayer, Monsanto’s parent company, continues to face. The initial verdict was one of the largest in the history of the Roundup litigation, reflecting the jury’s strong response to evidence presented against Monsanto. The reduction was likely based on legal caps on punitive damages and other considerations, but it remains a critical point in the ongoing litigation saga.
Meanwhile, in New Jersey, the state’s Supreme Court made a pivotal decision by denying a motion to consolidate the Roundup cases into a multicounty litigation (MCL). This decision is significant because it means that plaintiffs will continue to file their cases individually in their respective counties rather than having them grouped together in a single, large-scale litigation. The court’s ruling was based on an assessment that the current volume of cases did not meet the threshold required for broader consolidation, suggesting that the court is mindful of the complexities and potential inconsistencies that could arise from a mass grouping of cases.
On the federal level, the Roundup multidistrict litigation remains relatively stable, with a small influx of new cases. In the past month, only six new cases were added, bringing the total number of cases in the MDL to 2,285. While this marks a slight increase, it’s evident that much of the litigation energy is currently centered in state courts, where individual cases are being aggressively pursued. The MDL continues to serve as a crucial hub for coordinating discovery and pretrial proceedings, but its role has become more circumscribed as state-level actions gain prominence.
Bayer, which acquired Monsanto in 2018, continues to deal with the immense legal and financial pressures stemming from the Roundup litigation. The company’s CEO has described the ongoing lawsuits as an “existential threat” to Bayer’s future, highlighting the severe implications these cases have for the company’s financial health and long-term viability. Despite this, Bayer is exploring various legal strategies to mitigate its liabilities. This includes lobbying for legislative changes that could potentially reduce their exposure to future claims. However, the likelihood of such changes remains uncertain, particularly given the contentious nature of the Roundup cases and the strong opposition from advocacy groups and affected individuals.
Settlements in the Roundup cases are continuing, but with wide variability in the amounts being awarded. Depending on the specifics of each case—such as the severity of the plaintiff’s illness and the strength of the evidence linking their condition to Roundup exposure—settlement amounts have ranged from as low as $5,000 to as high as $250,000. These figures reflect the individual nature of the lawsuits, where each case is weighed on its own merits. While Bayer reached a substantial global settlement in 2020 to resolve many of the claims, thousands of cases remain unresolved, and new lawsuits continue to be filed. The process of reaching settlements is ongoing, with both plaintiffs and Bayer weighing the potential risks and benefits of continued litigation versus negotiated agreements.
A significant legal development occurred when an Oregon appellate court overturned Monsanto’s prior trial victory. The court ruled that the exclusion of key expert testimony from Dr. Charles Benbrook, who had been critical of the EPA’s handling of glyphosate, was an error. The court argued that Benbrook’s testimony could have helped clarify how Roundup’s regulatory framework might contribute to cancer risks. This ruling opens the door for a retrial, marking an important moment in the ongoing litigation against Monsanto regarding its herbicide Roundup.
At the same time, Bayer, Monsanto’s parent company, has intensified its efforts to influence legislation. In late June 2024, Bayer successfully pushed a bill through a Congressional subcommittee that includes preemption language designed to limit states’ regulatory power over pesticides. If passed, this could significantly reduce the number of lawsuits related to Roundup by blocking state-level legal actions. Bayer is also targeting state legislatures to limit its liabilities, showing that the company is aggressively pursuing legal and legislative strategies to mitigate the financial fallout from these lawsuits.
Additionally, court rulings have adjusted prior verdicts in favor of plaintiffs. In June, a judge reduced a $2.25 billion jury award to $404 million, citing that the original amount was excessive given the nature of the claims. Despite this reduction, the large sum still sends a clear message regarding the potential dangers of Roundup and Monsanto’s responsibility. These developments show that, while Bayer continues to fight in the courts and legislature, it faces ongoing legal challenges related to glyphosate exposure and its link to cancer.
On June 4, 2024, a Pennsylvania judge reduced the previous $2.25 billion verdict against Monsanto to $400 million, comprising $50 million in compensatory damages and $350 million in punitive damages. Both the plaintiff and Monsanto have decided to appeal this decision. As of June 2024, there were 4,279 Roundup lawsuits pending in the multidistrict litigation (MDL) in California. This number reflects the steady flow of new cases being added, emphasizing the ongoing legal challenges faced by Bayer, Monsanto’s parent company.
Despite the reduction in the McKivison case, plaintiffs have seen several favorable verdicts. This includes cases where juries have been awarded substantial sums, reinforcing the link between Roundup and cancer, particularly non-Hodgkin’s lymphoma. However, Monsanto continues to challenge these verdicts, seeking to overturn or reduce the awards.
In parallel, there is ongoing regulatory scrutiny and legislative action concerning glyphosate, Roundup’s active ingredient. This includes re-evaluations by health organizations and legislative proposals aimed at stricter regulations on glyphosate use and improved safety protocols for agricultural workers. If you or a loved one have developed serious health issues due to using Monsanto products, you don’t want to hesitate. It’s important to join in on the ongoing lawsuit and receive the compensation necessary to recover. Reach out to legal counsel to get more information about the growing cases surrounding Monsanto Roundup.
Our focus is on making sure that that you receive the attention you need and a clear path forward, all without any upfront costs. Our no-cost, no-obligation consultation outlines the steps we will take to fight for the justice and compensation you deserve.
DV Injury provides more than strong legal representation. We give you the support and reassurance you need during a challenging time in your life. Our goal is to ensure you’re not fighting the big corporations by yourself. We fight for you, and we don’t stop until justice is served.
You deserve the maximum amount for your distress and we do our level best to make sure you are properly compensated for pain and suffering, lost wages, medical expenses, and more. We’ve helped our clients recover hundreds of millions.
Contact us today for a free initial consultation.
We do not get paid unless you win.
Call or fill out the form below. We’ll contact you to schedule your free consulation.
